HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

Neutralizing antibody titres (geometric mean titres in each group) after immunization with an inactivated BoHV-1 265gE- vaccine, challenge with wild type virus (SV265 wt) and

We hereby demonstrate that immunization with the HIVBr27 vaccine encoding multiple conserved and promiscuous HIV-1 M- group consensus peptides is able to elicit broad, cross-clade

An equally enhanced T cell response was observed upon immunization with the V3 CTL epitope of the envelope (env) protein of the HIV-1 virus, expressed by reFlu, followed by a

Indeed, the presence of cross reactive T cell immunity is associated with protection in humans [11–13] and animals studies in which NP is delivered either as a recombinant protein

Absorbance in optical density (492 nm) for foals delivered by mares vaccinated with rEMA-2 of Theileria equi vaccine (n=9) and for foals delivered by control mares (n=9)

Currently, several candidates for an EV-A71 vaccine exist, including a formalin-inactivated whole virus vaccine, DNA vaccines, VLP and recombinant protein vaccines..

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T- cell responses

ing LigBrep as antigen and Alhydrogel as adjuvant, and determined the efficacy of these vaccination strategies in eliciting an IgG antibody response and in affording protective